COVID-19 Disease Clinical Trial
Official title:
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk of complications.
RESOLUTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2/3 study of LAU-7b for the treatment of COVID-19 Disease in patients at a higher risk than the general COVID-19 Disease population to develop complications while hospitalized. The goal of the study is to evaluate the efficacy of LAU-7b therapy + standard-of-care relative to placebo + standard-of-care in patients with COVID-19 Disease with confirmed SARS-CoV-2 infection. The purpose of the treatment with LAU-7b is to prevent the worsening of the health of hospitalized patients including aggravation such as recourse to mechanical ventilation and death. The means are the direct effects of LAU-7b on the resolution of inflammation, interference with viral proliferation and protection from excessive pro-inflammatory response. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04984408 -
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
|
Phase 3 | |
Terminated |
NCT04642638 -
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
|
Phase 2/Phase 3 | |
Recruiting |
NCT04587323 -
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
|
||
Completed |
NCT04682873 -
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
|
Phase 3 | |
Completed |
NCT04359212 -
Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19
|
||
Completed |
NCT05603130 -
Epidemiologic Register on Diabetes and COVID-19 in Tunisia
|
||
Completed |
NCT04830800 -
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC
|
Phase 1/Phase 2 | |
Completed |
NCT04757792 -
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
|
||
Recruiting |
NCT04522037 -
Measurement of the Efficacy of MORPHINE in the Early Management of Dyspnea in COVID-19 Positive Patients
|
||
Completed |
NCT04446377 -
A Study of LAM-002A for the Prevention of Progression of COVID-19
|
Phase 2 | |
Active, not recruiting |
NCT04969172 -
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
|
Phase 2 | |
Completed |
NCT04347369 -
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
|
||
Completed |
NCT04366024 -
A Novel Nomogram to Predict Severity of COVID-19
|
||
Completed |
NCT04787510 -
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
|
||
Completed |
NCT05329220 -
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
|
Phase 3 | |
Active, not recruiting |
NCT05077267 -
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
|
Phase 2 | |
Completed |
NCT04472013 -
Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
|
||
Active, not recruiting |
NCT04371354 -
Outcomes of Covid-19 Protective Measures in Endoscopy
|
||
Not yet recruiting |
NCT04779359 -
Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
|